Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
20.06B
Market cap20.06B
Price-Earnings ratio
-7.00
Price-Earnings ratio-7.00
Dividend yield
Dividend yield
Average volume
6.66M
Average volume6.66M
High today
$51.62
High today$51.62
Low today
$47.96
Low today$47.96
Open price
$49.10
Open price$49.10
Volume
8.18M
Volume8.18M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 20.06B, Moderna(MRNA) trades at $51.20. The stock has a price-to-earnings ratio of -7.00.

On 2026-04-01, Moderna(MRNA) stock traded between a low of $47.96 and a high of $51.62. Shares are currently priced at $51.20, which is +6.8% above the low and -0.8% below the high.

Moderna(MRNA) shares are trading with a volume of 8.18M, against a daily average of 6.66M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

MRNA News

TipRanks 16h
Option traders moderately bearish in Moderna with shares up 3.7%

Option traders moderately bearish in Moderna (MRNA), with shares up $1.78, or 3.7%, near $50.02. Options volume relatively light with 15k contracts traded and p...

Simply Wall St 4d
Moderna Faces EMA Approval And FDA Pushback As Valuation Risks Mount

Moderna (NasdaqGS:MRNA) has received European Medicines Agency approval for its mRNA flu vaccine, following efficacy data in older adults. In the U.S., the FDA...

Moderna Faces EMA Approval And FDA Pushback As Valuation Risks Mount
Nasdaq 7d
Moderna Stock is Soaring. Is It Too Late to Buy?

Key Points Moderna’s first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitt...

Moderna Stock is Soaring. Is It Too Late to Buy?

Analyst ratings

69%

of 26 ratings
Buy
15.4%
Hold
69.2%
Sell
15.4%

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.